Skip to main content

Day: July 14, 2021

Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience and proven track record in strategic investments, equity capital markets, and partnershipsSean GrantCFO, Vera TherapeuticsSOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics’ financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury. Marshall Fordyce, MD, founder and CEO of...

Continue reading

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Delaney brings his significant expertise in commercial oncology drug launches. BeyondSpring’s lead developmental asset, plinabulin, is currently under Priority Review by the U.S. Food and Drug Administration (FDA) for the prevention of chemotherapy-induced neutropenia (CIN) with a U.S. Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021. Mr. Delaney is expected to play an important role in the commercial launch planning for plinabulin and implementation, pending successful regulatory review. “We couldn’t be...

Continue reading

Ian Burnstein Joins Wesana Health Advisory Board

TORONTO and CHICAGO, July 14, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of Ian Burnstein to its Scientific Advisory Board. In this role, Burnstein will provide strategic guidance and direction to Wesana’s executive team, footprint expansion efforts, and overall company efforts related to the research and treatment of traumatic brain injury (TBI). Burnstein brings a deep understanding of investment strategies, entrepreneurship, market knowledge, and philanthropy. He is the principal and co-founder of Equitable Advisors,...

Continue reading

Orezone Provides Construction Update on Bomboré Gold Project

Figure 1Off Channel Reservoir MiningFigure 2New Nobsin River Bridge CrossingFigure 3Fuel Storage Area under constructionFigure 4Surface Water Management Pond under constructionFigure 5Orezone hosts the Burkina Faso Minister of Energy and Mines, and Coris Bank at Bomboré, June 2021VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX.V: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide an update on construction progress at its Bomboré Gold Project in Burkina Faso. Patrick Downey, President and CEO stated, “Significant progress has been achieved during the first half of 2021 and I am very pleased to report that the project capital cost remains consistent with the estimate in the 2019 Feasibility...

Continue reading

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control over clinical and initial commercial supply IND submission for hemophilia A now planned for 2023; factor VIII expression data with RES material in non-human primates expected year-end 2021 CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that it plans to deploy next-generation rapid enzymatic synthesis (RES) for manufacturing of its closed-ended DNA (ceDNA) constructs across all portfolio programs. RES...

Continue reading

Monro, Inc. to Report First Quarter Fiscal 2022 Earnings on July 28, 2021

ROCHESTER, N.Y., July 14, 2021 (GLOBE NEWSWIRE) — Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, will release its fiscal 2022 first quarter earnings on July 28, 2021. The Company will host a conference call and audio webcast on Wednesday, July 28, 2021 at 8:30 a.m. Eastern Time. The conference call may be accessed by dialing 1-877-425-9470 and using the required passcode 13721510. A replay will be available approximately two hours after the recording through Wednesday, August 11, 2021 and can be accessed by dialing 1-844-512-2921 and using the required passcode of 13721510. The live conference call and replay can also be accessed via audio webcast at the Investors section of the Company’s website, located at corporate.monro.com. An archive will be available at this website through...

Continue reading

Life Clips To Enter Cryptocurrency Market With A Definitive Agreement To Acquire Global Blockchain And Digital Currency Platform Belfrics Group

Life Clips plans to enter the $2 trillion cryptocurrency market by acquiring Belfrics Group AVENTURA, Fla., July 14, 2021 (GLOBE NEWSWIRE) — Life Clips, Inc. (OTC Pink: LCLP) (the “Company”, “Life Clips”), announced today it has agreed to acquire Belfrics Group (“Belfrics”), a global blockchain technology firm that runs cryptocurrency exchanges on its proprietary platform. Belfrics currently has a presence in Malaysia, Singapore, India, Kenya, Tanzania, Nigeria, and Bahrain; and it has the capability to process over 1 million transactions per second. Belfrics CEO and Founder, Praveen Kumar, will remain the CEO of Belfrics, while Robert Grinberg will serve as CEO of Life Clips. The cryptocurrency market is expected to reach $8 trillion dollars by 2030, while the market for blockchain technology is expected to add $176...

Continue reading

ParcelPal Announces Expansion into the United States via Entry Into “Letter of Intent” to Acquire a U.S. Delivery Company

VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) — ParcelPal Logistics Inc. (the “Company” or “ParcelPal”), (OTC:PTNYF) (CSE:PKG) (FSE:PT0) is pleased to announce that it has signed a “letter of intent” with a United States delivery service company (“Acquiree”). In its most recent fiscal year 2020, Acquiree generated gross revenues of approximately $4.6M USD. The total purchase price (the “Purchase Price”) is expected to be $3.1 million USD, payable in cash (60%) and in restricted shares of ParcelPal common stock (40%, which shall be priced at-market based on the closing price of the common stock following the closing of the transaction).   Under the terms of the proposed transaction, ParcelPal will acquire 95% of the outstanding shares of Acquiree’s capital stock, and Acquiree will enter into an exclusive services agreement...

Continue reading

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen’s QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. “We are excited to have reached this important milestone of submitting our first IND application to the FDA on our most advanced therapeutics program. This submission of the IND application for Phase 1b/2a clinical trials for QN-165...

Continue reading

Sundt Air Proudly Adds Third Bombardier Challenger Business Jet to its Fleet

Challenger 350Sundt Air, Norway’s largest business jet operator, will offer its newest Challenger 350 business jet for charter out of Oslo, NorwayChallenger 350 aircraft boasts an unparalleled cabin, a smooth ride and the lowest direct operating costs in its category Sundt Air, Norway’s largest business jet operator, will offer its newest Challenger 350 business jet for charter out of Oslo, NorwayMONTREAL, July 14, 2021 (GLOBE NEWSWIRE) — Bombardier and Sundt Air are pleased to announce the recent delivery of a brand-new Challenger 350 business jet. Sundt Air, an executive charter, aircraft management, and special mission company based in Norway, will manage the Challenger 350 business jet out of Oslo. The aircraft will be available for charter starting in July 2021. “The Challenger 350 business jet allows passengers...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.